Lysyl oxidase: A colorectal cancer biomarker of lung and hepatic metastasis.

Yun Liu,Guanghui Wang,Zhonglin Liang,Zubing Mei,Tingyu Wu,Ang Cui,Chenying Liu,Long Cui

DOI: https://doi.org/10.1111/1759-7714.12645

IF: 3.223

2018-01-01

Thoracic Cancer

Abstract:BackgroundColorectal cancer (CRC) is a common and lethal disease in which distant metastasis remains the primary cause of death. Paradoxical roles of LOX have been reported in CRC, and the intracellular function of LOX has also recently been determined. Correlations of LOX expression and its intracellular localization with clinicopathological features in CRC patients remain largely unknown. The aim of the present study was to explore the potential roles of LOX in CRC. MethodsLOX messenger RNA expression was assayed by quantitative PCR in eight paired normal mucosa and tumor tissues. Immunohistochemistry was conducted using tissue arrays to investigate LOX expression in 201 CRC patients. Regulation of LOX by YAP and TEAD4 was explored by YAP or TEAD4 short hairpin RNA interference in a LoVo cell line. ResultsLOX messenger RNA expression was elevated in some CRC specimens, and LOX nuclear localization was detected in CRC tumor tissues. LOX nuclear localization was found to correlate with lung/hepatic metastasis, elevated serum carcinoembryonic antigen concentration, and mucinous tumor type (P<0.05). Nuclear LOX expression was found to be associated with poor overall and disease-free survival (P<0.05), and postoperative lung/hepatic metastasis (P<0.05). Knockdown of YAP or TEAD4 induced downregulation of LOX expression. ConclusionsLOX nuclear localization was significantly associated with poor survival in patients with CRC. Nuclear LOX expression was correlated with synchronous or postoperative lung/hepatic metastasis. LOX may prove to be a potential target gene of YAP and TEAD4.